Evidence map›Paper›PMID 40613869›Full record

ArticleClinical and experimental nephrology2025

Post-transplantation management of hyperparathyroidism and its association with kidney graft survival and fibrosis.

Manabu Okada, Tetsuhiko Sato, Tomoki Himeno, Yuki Hasegawa, Yuki Shimamoto, Kenta Futamura, Takahisa Hiramitsu, Norihiko Goto, Shunji Narumi, Asami Takeda and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Manabu OkadaDepartment of Transplant Surgery and Transplant Nephrology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan. ubanamadako@yahoo.co.jp.ORCID http://orcid.org/0000-0002-8446-7841
Tetsuhiko SatoDepartment of Diabetes and Endocrinology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Tomoki HimenoDepartment of Transplant Surgery and Transplant Nephrology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Yuki HasegawaDepartment of Transplant Surgery and Transplant Nephrology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Yuki ShimamotoDepartment of Transplant Surgery and Transplant Nephrology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Kenta FutamuraDepartment of Transplant Surgery and Transplant Nephrology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Takahisa HiramitsuDepartment of Transplant Surgery and Transplant Nephrology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Norihiko GotoDepartment of Transplant Surgery and Transplant Nephrology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Shunji NarumiDepartment of Transplant Surgery and Transplant Nephrology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Asami TakedaDepartment of Nephrology, Masuko Memorial Hospital, Nagoya, Japan.
Toshihiro IchimoriDepartment of Transplant Surgery and Transplant Nephrology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Yoshihiko WataraiDepartment of Transplant Surgery and Transplant Nephrology, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHyperparathyroidism (HPT) is a potential risk factor for graft loss after kidney transplantation (KTx). However, the effects of HPT management on graft outcomes remain unclear. This retrospective study aimed to investigate the impact of HPT status and its management on graft outcomes.

methodsPatients who underwent KTx were categorized based on their HPT status and treatment at 1-year post-KTx into four groups: normal (no HPT), normocalcemic HPT, hypercalcemic HPT, or intervention (parathyroidectomy or calcimimetics within 1 year after KTx). Patients treated for HPT beyond the first year post-KTx were censored. The primary outcome was death-censored graft survival and the secondary outcome was the progression of interstitial fibrosis and tubular atrophy (IFTA) at 1-year post KTx.

resultsAmong 1264 patients, the 10-year death-censored graft-survival rate was lowest in the hypercalcemic HPT group (79.7%), whereas the intervention group had a survival rate of 100.0%. In the multivariate Cox regression analysis, hypercalcemic HPT was associated with an increased risk of graft loss (fully adjusted hazard ratio [HR] = 4.25, P = 0.001, compared to the normal group). Contrarily, the intervention group did not show an increased risk of graft loss (fully adjusted HR = 0.28, P = 0.239). Additionally, hypercalcemia during the first year after KTx was significantly associated with IFTA progression (fully adjusted odds ratio = 1.91, P = 0.038).

conclusionHypercalcemic HPT was associated with inferior graft survival and IFTA progression. Proactive management of HPT may reduce the risk of graft loss and mitigate IFTA progression.

Indexed as

Calcimimetic AgentsGraft SurvivalHyperparathyroidismKidneyKidney TransplantationParathyroidectomyAdultAtrophyDisease ProgressionFemaleFibrosisHumansHypercalcemiaMaleMiddle AgedRetrospective StudiesCalcimimetic AgentsCalcimimeticsHyperparathyroidismInterstitial fibrosis and tubular atrophyKidney transplantationParathyroidectomy

Identifiers

PMID40613869
PMCPMC12660426

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.